Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Center of Excellence in Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.
Crit Rev Biotechnol. 2023 Sep;43(6):823-834. doi: 10.1080/07388551.2022.2071672. Epub 2022 Jun 27.
Cannabis is widely recognized as a medicinal plant owing to bioactive cannabinoids. However, it is still considered a narcotic plant, making it hard to be accessed. Since the biosynthetic pathway of cannabinoids is disclosed, biotechnological methods can be employed to produce cannabinoids in heterologous systems. This would pave the way toward biosynthesizing any cannabinoid compound of interest, especially minor substances that are less produced by a plant but have a high medicinal value. In this context, microalgae have attracted increasing scientific interest given their unique potential for biopharmaceutical production. In the present review, the current knowledge on cannabinoid production in different hosts is summarized and the biotechnological potential of microalgae as an emerging platform for synthetic production is put in perspective. A critical survey of genetic requirements and various transformation approaches are also discussed.
大麻因其具有生物活性的大麻素而被广泛认为是一种药用植物。然而,它仍然被视为麻醉植物,难以获得。由于大麻素的生物合成途径已经被揭示,因此可以采用生物技术方法在异源系统中生产大麻素。这将为合成任何感兴趣的大麻素化合物铺平道路,特别是那些植物产量较少但药用价值高的次要物质。在这种情况下,由于其在生物制药生产方面的独特潜力,微藻引起了越来越多的科学兴趣。在本综述中,总结了不同宿主中大麻素生产的现有知识,并从合成生产的新兴平台的角度来看待微藻的生物技术潜力。还讨论了遗传要求和各种转化方法的批判性调查。